Imunon (NASDAQ:IMNN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Imunon to post earnings of ($0.36) per share for the quarter.
Imunon Price Performance
IMNN opened at $0.86 on Tuesday. The stock has a market cap of $12.50 million, a P/E ratio of -0.46 and a beta of 2.03. The stock’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $0.95. Imunon has a 1-year low of $0.57 and a 1-year high of $3.65.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. D. Boral Capital restated a “buy” rating and issued a $29.00 price target on shares of Imunon in a report on Wednesday, February 19th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a report on Thursday, December 19th.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Read More
- Five stocks we like better than Imunon
- How to start investing in penny stocks
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- What Are Dividend Challengers?
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Why is the Ex-Dividend Date Significant to Investors?
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
